Campbells Co (NASDAQ: CPB) – Suitable For Long Term Buy?

Currently, there are 298.00M common shares owned by the public and among those 196.45M shares have been available to trade.

The company’s stock has a 5-day price change of 2.24% and -17.05% over the past three months. CPB shares are trading -18.22% year to date (YTD), with the 12-month market performance down to -21.12% lower. It has a 12-month low price of $32.95 and touched a high of $52.81 over the same period. CPB has an average intraday trading volume of 3.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.69%, -6.60%, and -19.09% respectively.

Institutional ownership of Campbells Co (NASDAQ: CPB) shares accounts for 58.41% of the company’s 298.00M shares outstanding.

It has a market capitalization of $10.21B and a beta (3y monthly) value of 0.11. The stock’s trailing 12-month PE ratio is 22.63, while the earnings-per-share (ttm) stands at $1.51. The company has a PEG of 27.26 and a Quick Ratio of 0.33 with the debt-to-equity ratio at 1.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.21% over the week and 1.67% over the month.

Analysts forecast that Campbells Co (CPB) will achieve an EPS of 0.66 for the current quarter, 0.89 for the next quarter and 3.02 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.55 while analysts give the company a high EPS estimate of 0.55. Comparatively, EPS for the current quarter was 0.63 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.93%, and 0.51% over the next financial year. EPS should shrink at an annualized rate of 0.83% over the next five years, compared to 15.98% over the past 5-year period.

Looking at the support for the CPB, a number of firms have released research notes about the stock. UBS stated their Sell rating for the stock in a research note on April 23, 2025, with the firm’s price target at $36. JP Morgan was of a view on March 06, 2025 that the stock is Neutral, while Piper Sandler gave the stock Overweight rating on November 14, 2024, issuing a price target of $47- $56. Bernstein on their part issued Outperform rating on October 07, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.